Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: Relationship between efficacy and tumor genotype in Korean patients

Keyphrases

• Second-line Therapy 100%
• Sunitinib 100%
• Advanced Gastrointestinal Stromal Tumor 100%
• Imatinib 100%
• Korean Patients 100%
• Tumor Genotyping 100%
• Gastrointestinal Stromal Tumor 80%
• Exon 9 60%
• Time to Progression 40%
• Medical Center 20%
• Tumor 20%
• Clinical Data 20%
• Genotype 20%
• Initial Treatment 20%
• Thrombocytopenia 20%
• Stable Disease 20%
• Clinical Benefit 20%
• Neutropenia 20%
• Platelet-derived Growth Factor Receptor (PDGFR) 20%
• Asan 20%
• Adverse Events 20%
• Statistical Significance 20%
• Consecutive Patients 20%
• Median Time 20%
• Objective Response 20%
• Exon 18 20%
• Exon 12 20%
• Overall Survival Time 20%
• Hand-foot Skin Reaction 20%
• Western Experience 20%
• KIT Exon 11 20%

Medicine and Dentistry

• Neoplasm 100%
• Sunitinib 100%
• Gastrointestinal Stromal Tumor 100%
• Imatinib 100%
• Exon 71%
• Disease 14%
• Adverse Event 14%
• Neutropenia 14%
• Overall Survival 14%
• Survival Time 14%
• Thrombocytopenia 14%
• Clinical Method 14%
• Hand Foot Syndrome 14%